Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 5/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622542 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620608 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4403101 | 0.86 | ALOX15 (0.54) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL1883225 | 0.86 | ALOX15 (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30193757 | 0.86 | ALOX15 (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620607 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620680 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL25748437 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620609 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL8959852 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020244462-A1 | INDOLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2020-12-10 | — | — | WO | disclosed |
| EP-1390029-B1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2009-12-16 | — | — | EP | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| EP-1390029-A4 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2005-11-30 | — | — | EP | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710068-B2 | PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS | IDENIX PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1390029-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | Idenix (Cayman) Limited (KY) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002083126-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX (CAYMAN) LIMITED (KY) | 2002-10-24 | — | — | WO | disclosed |
| US-6271251-B1 | CARDIOVASCULAR DISORDERS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2001-08-07 | — | — | US | disclosed |
| US-5977100-A | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5834454-A | TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5494928-A | FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885ALDH1A1 1178/4885RAB9A 2298/4885 |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885ALDH1A1 1178/4885RAB9A 2298/4885 |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885ALDH1A1 1178/4885RAB9A 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.